Understanding The Potential Therapeutic and Diagnostic Applications of KCNQ3

Target Name: KCNQ3

NCBI ID: G3786

KCNQ3

Other Name(s): KV7.3 | Potassium voltage-gated channel subfamily KQT member 3 (isoform 2) | potassium channel, voltage gated KQT-like subfamily Q, member 3 | voltage-gated potassium channel subunit Kv7.3 | KCNQ3 variant 1 | Potassium voltage-gated channel, KQT-like subfamily, member 3 | KQT-like 3 | KCNQ3_HUMAN | Potassium voltage-gated channel subfamily KQT member 3 | potassium channel subunit alpha KvLQT3 | Potassium channel subunit alpha KvLQT3 | BFNC2 | Potassium channel, voltage gated KQT-like subfamily Q, member 3 | Voltage-gated potassium channel subunit Kv7.3 | Kv7.3 | Potassium channel, voltage-gated, subfamily Q, member 3 | Potassium voltage-gated channel subfamily Q member 3, transcript variant 2 | potassium voltage-gated channel subfamily Q member 3 | Potassium voltage-gated channel subfamily KQT member 3 (isoform 1) | EBN2 | potassium voltage-gated channel, KQT-like subfamily, member 3 | KCNQ3 variant 2 | potassium channel, voltage-gated, subfamily Q, member 3 | Potassium voltage-gated channel subfamily Q member 3, transcript variant 1

Understanding The Potential Therapeutic and Diagnostic Applications of KCNQ3

KCNQ3 (KV7.3), a protein known for its role in the regulation of ion channels and neurotransmitter release, has recently been identified as a potential drug target and biomarker for various neurological and psychiatric disorders. The structure and function of KCNQ3 have been extensively studied, and its potential implications for human disease have been discussed in this article.

KCNQ3 is a member of the selective ion channel subfamily of the voltage-dependent Na+ channels, which are responsible for generating action potentials in the nervous system. These channels play a crucial role in the transmission of information in the brain, and their dysfunction has been implicated in a wide range of neurological and psychiatric disorders.

One of the key functions of KCNQ3 is its role in the regulation of neurotransmitter release. These molecules are responsible for transmitting signals from the brain to the rest of the body and are critical for the regulation of mood, behavior, and other physiological processes. The release of neurotransmitters is regulated by ion channels, including KCNQ3, and abnormal levels of neurotransmitters can have serious implications for human health.

KCNQ3 has been shown to play a crucial role in the regulation of neurotransmitter release in the brain. Studies have shown that mice that have been genetically modified to lack forskolin, a compound that can modulate the activity of KCNQ3, have increased levels of neurotransmitters, including dopamine and serotonin, in the brain. This suggests that modulating the activity of KCNQ3 may be a potential approach for treating psychiatric disorders that are characterized by increased levels of neurotransmitters.

In addition to its role in neurotransmitter release, KCNQ3 has also been shown to play a crucial role in the regulation of ion channels. Studies have shown that modulating the activity of ion channels, including those in the brain, can have a profound impact on brain function. This suggests that modulating the activity of ion channels, including KCNQ3, may be a potential approach for treating a wide range of neurological and psychiatric disorders.

The potential implications of modulating the activity of KCNQ3 are vast and varied. For example, modulating the activity of KCNQ3 may be a potential approach for treating psychiatric disorders that are characterized by increased levels of neurotransmitters, such as depression and anxiety. It may also be a potential approach for treating other neurological disorders, such as epilepsy and Alzheimer's disease.

In addition to its potential therapeutic applications, modulating the activity of KCNQ3 may also have potential diagnostic applications. The regulation of ion channels, including those in the brain, is a critical function of the nervous system, and abnormal levels of these channels can be a sign of underlying neurological or psychiatric disorders. Therefore, modulating the activity of KCNQ3 may be a potential approach for diagnosing a wide range of psychiatric and neurological disorders.

Overall, KCNQ3 is a protein that has important roles in the regulation of ion channels and neurotransmitter release in the nervous system. Its potential as a drug target and biomarker for a wide range of psychiatric and neurological disorders makes it an attractive target for further research and development. Further studies are needed to fully understand the role of KCNQ3 in human disease and to develop safe and effective treatments.

Protein Name: Potassium Voltage-gated Channel Subfamily Q Member 3

Functions: Associates with KCNQ2 or KCNQ5 to form a potassium channel with essentially identical properties to the channel underlying the native M-current, a slowly activating and deactivating potassium conductance which plays a critical role in determining the subthreshold electrical excitability of neurons as well as the responsiveness to synaptic inputs. Therefore, it is important in the regulation of neuronal excitability. KCNQ2-KCNQ3 channel is selectively permeable to other cations besides potassium, in decreasing order of affinity K(+) > Rb(+) > Cs(+) > Na(+). Associates with Na(+)-coupled myo-inositol symporter SLC5A3 forming a coregulatory complex that alters ion selectivity, increasing Na(+) and Cs(+) permeation relative to K(+) permeation (PubMed:28793216)

The "KCNQ3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KCNQ3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets